|
Sanofi's dual-action biotech asthma drug performs well in test
Reuters Nov 11 (Reuters) – An experimental biotech drug for severe asthma from France's Sanofi and its U.S. partner Regeneron has produced good results in clinical tests, suggesting its dual-action mechanism may be highly effective. Dupilumab is a latecomer … Regeneron and Sanofi Announce Positive Results from Phase 2b Study of … Regeneron, Sanofi Say Phase 2b trial of Dupilumab Meets Primary Endpoint |
View full post on asthma – Google News